Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Cytokinetics CEO Robert Blum exercised 7,500 stock options at a strike price of $10.60 and sold them at a weighted-average price of $76.76, generating $575,700. Despite the sale, Blum retains substantial equity holdings of 377,820 direct shares and 4,166 indirect shares, indicating continued alignment with shareholders. Analysts view the transaction as routine profit-taking given the stock's 100% gain over the past 12 months, with 91% of analysts rating the stock a buy and a median price target of $107.50.